Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/american-medical-association/effect-of-2-inactivated-sars-cov-2-vaccines-on-symptomatic-covid-19-t3gR2wErWQ
References (45)
-
Guo-Lin Wang, Zhuang Wang, L. Duan, Qing-Chuan Meng, Ming-dong Jiang, Jing Cao, Lin Yao, K. Zhu, W. Cao, M. Ma (2021)
Susceptibility of Circulating SARS-CoV-2 Variants to NeutralizationThe New England Journal of Medicine
-
Zejun Wang, Huajun Zhang, Jia Lu, K. Xu, Cheng Peng, Jing Guo, Xiaowei Gao, X. Wan, Wenhui Wang, Chao Shan, Suyun Zhang, Jie Wu, An-Na Yang, Yan Zhu, Ao Xiao, Lei Zhang, L. Fu, Hao-rui Si, Q. Cai, Xinglou Yang, Lei You, Yan-Ping Zhou, Jing Liu, De-Qing Pang, W. Jin, Xiao-Yu Zhang, Sheng-li Meng, Yunxiao Sun, U. Desselberger, Jun-zhi Wang, Xinguo Li, Kai Duan, Changgui Li, Miao Xu, Z. Shí, Zhiming Yuan, Xiao-Ming Yang, S. Shen (2020)
Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal modelsEmerging Microbes & Infections, 9
-
Supervision: Xia, Abdelhadi, Xiaoming Yang. REFERENCES 1. Draft landscape and tracker of COVID-19 candidate vaccines. World Health Organization -
Xia (2020)
951JAMA, 324
-
Supasa (2021)
2201Cell, 184
-
Wang (2021)
616Nature, 592
-
J. Sadoff, G. Gray, A. Vandebosch, V. Cárdenas, Georgi Shukarev, B. Grinsztejn, P. Goepfert, C. Truyers, H. Fennema, B. Spiessens, Kim Offergeld, Gert Scheper, K. Taylor, M. Robb, J. Treanor, D. Barouch, J. Stoddard, M. Ryser, M. Marovich, K. Neuzil, L. Corey, N. Cauwenberghs, T. Tanner, K. Hardt, J. Ruiz-Guiñazú, Mathieu Gars, H. Schuitemaker, J. Hoof, F. Struyf, M. Douoguih (2021)
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19The New England Journal of Medicine
-
P. Supasa, D. Zhou, W. Dejnirattisai, Chang Liu, A. Mentzer, H. Ginn, Yuguang Zhao, Helen Duyvesteyn, Rungtiwa Nutalai, A. Tuekprakhon, Beibei Wang, G. Paesen, J. Slon-Campos, C. López-Camacho, B. Hallis, N. Coombes, K. Bewley, S. Charlton, T. Walter, E. Barnes, S. Dunachie, D. Skelly, S. Lumley, Natalie Baker, Imam Shaik, H. Humphries, K. Godwin, N. Gent, Alex Sienkiewicz, C. Dold, R. Levin, T. Dong, A. Pollard, J. Knight, P. Klenerman, D. Crook, T. Lambe, E. Clutterbuck, S. Bibi, A. Flaxman, M. Bittaye, Sandra Belij-Rammerstorfer, S. Gilbert, D. Hall, Mark Williams, N. Paterson, W. James, M. Carroll, E. Fry, J. Mongkolsapaya, Jingshan Ren, D. Stuart, G. Screaton (2021)
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine seraCell, 184
-
Zijun Wang, F. Schmidt, Y. Weisblum, F. Muecksch, C. Barnes, Shlomo Finkin, Dennis Schaefer-Babajew, M. Cipolla, C. Gaebler, J. Lieberman, Thiago Oliveira, Zhi Yang, M. Abernathy, Kathryn Huey-Tubman, A. Hurley, Martina Turroja, K. West, Kristie Gordon, Katrina Millard, Victor Ramos, Justin Silva, Jianliang Xu, R. Colbert, R. Patel, Juan Dizon, Cecille Unson-O’Brien, I. Shimeliovich, A. Gazumyan, M. Caskey, P. Bjorkman, R. Casellas, T. Hatziioannou, P. Bieniasz, M. Nussenzweig (2021)
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variantsNature, 592
-
(2009)
WHO target product profiles for COVID-19 vaccines. World Health Organization -
Aisha Fakhroo, A. Thani, H. Yassine (2020)
Markers Associated with COVID-19 Susceptibility, Resistance, and SeverityViruses, 13
-
Polack (2020)
2603N Engl J Med, 383
-
Fakhroo (2020)
45Viruses, 13
-
D. Logunov, I. Dolzhikova, D. Shcheblyakov, A. Tukhvatulin, O. Zubkova, A. Dzharullaeva, A. Kovyrshina, N. Lubenets, D. Grousova, A. Erokhova, A. Botikov, F. Izhaeva, O. Popova, T. Ozharovskaya, I. Esmagambetov, I. Favorskaya, D. Zrelkin, D. Voronina, D. Shcherbinin, A. Semikhin, Y. Simakova, E. Tokarskaya, D. Egorova, M. Shmarov, N. Nikitenko, V. Gushchin, E. Smolyarchuk, S. Zyryanov, S. Borisevich, B. Naroditsky, A. Gintsburg (2021)
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in RussiaLancet (London, England), 397
-
F. Polack, Stephen Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, John Perez, Gonzalo Marc, E. Moreira, C. Zerbini, R. Bailey, K. Swanson, Satrajit Roychoudhury, K. Koury, Ping Li, W. Kalina, D. Cooper, R. Frenck, L. Hammitt, Ö. Türeci, H. Nell, A. Schaefer, S. Ünal, D. Tresnan, S. Mather, P. Dormitzer, U. Şahin, K. Jansen, W. Gruber (2020)
Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineThe New England Journal of Medicine
-
S. Xia, Kai Duan, Yuntao Zhang, D. Zhao, Huajun Zhang, Z. Xie, Xinguo Li, Cheng Peng, Yan-Bo Zhang, Wei Zhang, Y. Yang, Wei Chen, Xiaoxiao Gao, W. You, Xuewei Wang, Zejun Wang, Zhengli Shi, Yanxia Wang, Xuqin Yang, Lianghao Zhang, Lili Huang, Qian Wang, Jia Lu, Yongli Yang, Jing Guo, Wei Zhou, X. Wan, Cong Wu, Wenhui Wang, Shihe Huang, Jianhui Du, Z. Meng, A. Pan, Zhiming Yuan, S. Shen, Wanshen Guo, Xiaoming Yang (2020)
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.JAMA
-
Baden (2021)
403N Engl J Med, 384
-
Voysey (2021)
99Lancet, 397
-
I. Chan, N. Bohidar (1998)
Exact power and sample size for vaccine efficacy studiesCommunications in Statistics-theory and Methods, 27
-
Hui Wang, Yuntao Zhang, Baoying Huang, Wei Deng, Yaru Quan, Wenling Wang, Wenbo Xu, Yuxiu Zhao, Na Li, Jin Zhang, Hongyang Liang, L. Bao, Yanfeng Xu, L. Ding, Wei-min Zhou, Hong Gao, Jiangning Liu, P. Niu, Li Zhao, Wei Zhen, H. Fu, Shouzhi Yu, Zhengli Zhang, Guangxue Xu, Changgui Li, Z. Lou, Miao Xu, C. Qin, Guizhen Wu, G. Gao, W. Tan, Xiaoming Yang (2020)
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2Cell, 182
-
Wang (2020)
713Cell, 182
-
Lan (1983)
659Biometrika, 70
-
Kai Wu, Anne Werner, M. Koch, A. Choi, Elisabeth Narayanan, G. Stewart-Jones, T. Colpitts, H. Bennett, S. Boyoglu-Barnum, W. Shi, Juan Moliva, N. Sullivan, B. Graham, A. Carfi, Kizzmekia Corbett, R. Seder, D. Edwards (2021)
Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine - Preliminary Report.The New England journal of medicine
-
Wang (2021)
130Nature, 593
-
Obtained funding: Yuntao Zhang -
Wu (2021)
1468N Engl J Med, 384
-
K Wu, AP Werner, M Koch (2021)
Serum neutralizing activity elicited by mRNA-1273 vaccineN Engl J Med, 384
-
Pengfei Wang, M. Nair, Lihong Liu, S. Iketani, Yang Luo, Yicheng Guo, Maple Wang, Jian Yu, Baoshan Zhang, P. Kwong, B. Graham, J. Mascola, Jennifer Chang, M. Yin, M. Sobieszczyk, C. Kyratsous, L. Shapiro, Z. Sheng, Yaoxing Huang, D. Ho (2021)
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7Nature, 593
-
M. Voysey, S. Clemens, S. Madhi, L. Weckx, P. Folegatti, P. Aley, B. Angus, V. Baillie, S. Barnabas, Q. Bhorat, S. Bibi, C. Briner, P. Cicconi, A. Collins, Rachel Colin-Jones, C. Cutland, T. Darton, K. Dheda, Christopher Duncan, K. Emary, K. Ewer, L. Fairlie, S. Faust, S. Feng, D. Ferreira, A. Finn, A. Goodman, Catherine Green, C. Green, P. Heath, Catherine Hill, H. Hill, I. Hirsch, S. Hodgson, A. Izu, Susan Jackson, D. Jenkin, Carina Joe, S. Kerridge, A. Koen, G. Kwatra, R. Lazarus, A. Lawrie, Alice Lelliott, V. Libri, P. Lillie, R. Mallory, A. Mendes, E. Milan, A. Minassian, A. McGregor, Hazel Morrison, Y. Mujadidi, Anusha Nana, P. O’Reilly, S. Padayachee, Ana Pittella, E. Plested, K. Pollock, M. Ramasamy, S. Rhead, A. Schwarzbold, Nisha Singh, Andrew Smith, R. Song, M. Snape, E. Sprinz, R. Sutherland, R. Tarrant, E. Thomson, M. Török, M. Toshner, D. Turner, J. Vekemans, T. Villafana, Marion Watson, C.J. Williams, Alexander Douglas, A. Hill, T. Lambe, S. Gilbert, A. Pollard (2020)
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.Lancet
-
K. Lan, D. DeMets (1983)
Discrete sequential boundaries for clinical trialsBiometrika, 70
-
An international randomised trial of candidate vaccines against COVID-19. World Health Organization -
Yang Liu, Jianying Liu, Hongjie Xia, Xianwen Zhang, Camila Fontes-Garfias, K. Swanson, Hui Cai, Ritu Sarkar, Wei Chen, M. Cutler, D. Cooper, S. Weaver, A. Muik, U. Şahin, K. Jansen, Xuping Xie, P. Dormitzer, P. Shi (2021)
Neutralizing Activity of BNT162b2-Elicited Serum - Preliminary Report.The New England journal of medicine
-
Wang (2020)
2606Emerg Microbes Infect, 9
-
L. Baden, H. Sahly, B. Essink, K. Kotloff, S. Frey, R. Novak, D. Diemert, S. Spector, N. Rouphael, C. Creech, J. Mcgettigan, Shishir Kehtan, N. Segall, Joel Solis, A. Brosz, C. Fierro, H. Schwartz, K. Neuzil, L. Corey, P. Gilbert, H. Janes, D. Follmann, M. Marovich, J. Mascola, L. Polakowski, J. Ledgerwood, B. Graham, H. Bennett, R. Pajon, C. Knightly, B. Leav, W. Deng, Honghong Zhou, Shu Han, M. Ivarsson, Jacqueline Miller, T. Zaks (2020)
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineThe New England Journal of Medicine
-
Chan (1998)
1305Commun Stat Theory Methods, 27
-
Logunov (2021)
671Lancet, 397
-
Y Liu, J Liu, H Xia (2021)
Neutralizing activity of BNT162b2-elicited serumN Engl J Med, 384
-
Xia (2021)
39Lancet Infect Dis, 21
-
S. Xia, Yuntao Zhang, Yanxia Wang, Hui Wang, Yunkai Yang, G. Gao, W. Tan, Guizhen Wu, Miao Xu, Z. Lou, Wei-jin Huang, Wenbo Xu, Baoying Huang, Huijuan Wang, Wen Wang, Wei Zhang, Na Li, Z. Xie, Li Ding, W. You, Yuxiu Zhao, Xuqin Yang, Yang Liu, Qianqian Wang, Lili Huang, Yongli Yang, Guangxue Xu, B. Luo, Wenling Wang, Peipei Liu, Wanshen Guo, Xiaoming Yang (2020)
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trialThe Lancet. Infectious Diseases, 21
-
Kyriakidis (2021)
28NPJ Vaccines, 6
-
(2021)
SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 Research Original Investigation Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults E10 -
S. Madhi, V. Baillie, C. Cutland, M. Voysey, A. Koen, L. Fairlie, S. Padayachee, K. Dheda, S. Barnabas, Q. Bhorat, C. Briner, G. Kwatra, K. Ahmed, P. Aley, S. Bhikha, J. Bhiman, A. Bhorat, J. Plessis, A. Esmail, M. Groenewald, E. Horne, Shi-Hsia Hwa, A. Jose, T. Lambe, M. Laubscher, M. Malahleha, Masebole Masenya, Mduduzi Masilela, S. Mckenzie, Kgaogelo Molapo, A. Moultrie, S. Oelofse, Faeezah Patel, S. Pillay, S. Rhead, H. Rodel, Lindie Rossouw, C. Taoushanis, H. Tegally, A. Thombrayil, Samuel Eck, C. Wibmer, N. Durham, E. Kelly, T. Villafana, S. Gilbert, A. Pollard, T. Oliveira, P. Moore, A. Sigal, A. Izu (2021)
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 VariantNew England Journal of Medicine, 384
-
N. Kyriakidis, A. López-Cortés, Erik González, Alejandra Grimaldos, Esteban Prado (2021)
SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidatesNPJ Vaccines, 6
-
Liu (2021)
1466N Engl J Med, 384
-
National Health Commission of the People's Republic of China
- Publisher
- American Medical Association
- Copyright
- Copyright 2021 American Medical Association. All Rights Reserved.
- ISSN
- 0098-7484
- eISSN
- 1538-3598
- DOI
- 10.1001/jama.2021.8565
- Publisher site
- See Article on Publisher Site
Abstract
Key PointsQuestionWhat is the efficacy of 2 inactivated SARS-CoV-2 vaccines for prevention of symptomatic COVID-19? FindingsThis prespecified interim analysis of a randomized clinical trial included 40 382 participants who received at least 1 dose of a 2-dose inactivated vaccine series developed from either SARS-CoV-2 WIV04 (5 µg/dose) or HB02 (4 µg/dose) strains or an aluminum hydroxide–only control, with a primary end point of the incidence of symptomatic COVID-19 at least 14 days after the second injection. The efficacy for the 2 vaccines, compared with an aluminum hydroxide–only control, was 72.8% in the WIV04 group and 78.1% in the HB02 group; both comparisons were statistically significant. MeaningTwo inactivated SARS-CoV-2 vaccines demonstrated efficacy against symptomatic COVID-19 compared with an aluminum hydroxide–only control.
Journal
JAMA – American Medical Association
Published: Jul 6, 2021